Septic shock and multiple organ failure after hematopoietic stem cell transplantation: treatment with recombinant human activated protein C

Abstract

Summary:Severe sepsis with multiple organ failure after hematopoietic stem cell transplantation (HSCT) results in extremely high morbidity and mortality. Recent studies have highlighted the importance of sepsis-induced activation of the coagulation system in the pathophysiology of severe sepsis. Activated protein C is an important modulator of coagulation and inflammatory derangements during severe sepsis. Low levels of protein C occur in severe sepsis and are predictive of poor outcome. Recombinant human activated protein C (drotrecogin alfa (activated)) was recently approved by the Food and Drug Administration (FDA) for severe sepsis. The phase III trial that resulted in the approval of this agent, however, enrolled a general sepsis population and excluded patients undergoing HSCT. We report a case of fulminant septic shock and multiple organ failure after HSCT that was treated with drotrecogin alfa (activated) in addition to standard therapy, and recovered. The high mortality rates of patients who develop severe sepsis after HSCT demand that new avenues of treatment be considered for this very highrisk patient population. This case illustrates the potential application of a novel therapeutic approach. Clinical trials are warranted to further investigate the safety and efficacy of drotrecogin alfa (activated) in patients with severe sepsis after HSCT.

Sepsis associated with immunosuppressive medications: An evidence-based review

“…A significant proportion of immunocompromised patients, however, may have one or more contraindications for the use of activated protein C. Anecdotal reports are being published (114), but until more experience is accumulated, no recommendation can be made.…”

Anti-inflammatory effects of benfotiamine are mediated through the regulation of the arachidonic acid pathway in macrophages

“…Overwhelming inflammatory responses accompanied by deregulated immunological and coagulation functions results in multiple organ failure leading to septic shock a major cause of mortality [1]. Although, treatment with the antibiotics kills bacteria and impedes the infection, the bacterial debris which contains large amounts of endotoxins could trigger the inflammatory responses [2].…”

Management of Infectious Complications in the Hematopoietic Stem Cell Transplant Recipient

“…Recombinant APC appeared to be effective in one recent case report of refractory septic shock with multiple organ dysfunction in a patient who was 2 months status post nonmyeloablative HSCT [32]. The characteristics of this patient-"late" after nonmyeloablative transplant and thus fully engrafted without thrombocytopenia-appeared to be ideal for APC therapy.…”